{"created":"2015-05-18T17:11:19+00:00","modified":"2015-05-18T17:11:20+00:00","valid":{"from":"2013-11-05T14:23:48+00:00","to":"3013-11-05T14:23:48+00:00"},"hreflang":"en","guid":"48d865e2-2ff9-4fbe-8339-9585f7b47527","title":"Johnson & Johnson to pay $2.2 billion in Risperdal settlement","published":"2013-11-05T14:23:48+00:00","byline":"Sabri Ben-Achour","teaser":"In one of the biggest cases of health care fraud ever, J&J is being fined for improperly marketing a drug for treating schizophrenia.","contenttemplated":"[{\"content\":\"<p>It is one of the biggest settlements of a health care fraud case ever. Johnson and Johnson has agreed to pay $2.2 billion to settle charges over how it aggressively marketed drugs in the late 90s and early 200s, including paying kickbacks to pharmacists.</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p><span><span>The pharmaceutical giant is accused of marketing its drug Risperdal, which is approved for treating schizophrenia, as a way to treat anxiety among elderly people with dementia, even though it increased their risk of death. </span><span>Doctors are allowed to </span><span>prescribe</span><span> drugs for unapproved or so-called &quot;off-label&quot; uses, but it is illegal for a company to market a drug in a way that it hasn&apos;t been approved by federal regulators. Prosecutors say the company also promoted the drug to treat mentally ill boys -- even though it could cause them to grow breasts. Johnson &amp; Johnson is currently fighting a large number of individual lawsuits related to those accusations. </span></span></p>\"},{\"content\":\"<p><span>In the settlement, Johnson &amp; Johnson pled guilty to “introducing a misbranded drug into interstate commerce.” But in a letter to its employees, company lawyers said they strongly dispute the government’s version of events and settled just to move on and avoid lengthy legal tie ups.  </span></p>\",\"type\":\"text/html\"},{\"content\":\"<p><span>By the way, the whistleblowers whose leaks spurred this investigation stand to gain about $168 million from the government’s taking.</span></p>\",\"type\":\"text/html\"}]","itags":["48d865e22ff9fbea33949585f7b47527","Marketplace","Marketplace Morning Report","Marketplace Morning Report for Tuesday, November 5, 2013","PMP:Marketplace_PMP"],"contentencoded":"<div class=\"barn-cleaned\"><p>It is one of the biggest settlements of a health care fraud case ever. Johnson and Johnson has agreed to pay $2.2 billion to settle charges over how it aggressively marketed drugs in the late 90s and early 200s, including paying kickbacks to pharmacists.</p>\n<p><span><span>The pharmaceutical giant is accused of marketing its drug&nbsp;Risperdal, which is approved for treating schizophrenia, as a way to treat anxiety among elderly people with dementia, even though it increased their risk of death.&nbsp;</span><span>Doctors are allowed to&nbsp;</span><span>prescribe</span><span>&nbsp;drugs for unapproved or so-called \"off-label\" uses, but it is illegal for a company to market a drug in a way that it hasn't been approved by federal regulators.&nbsp;Prosecutors say the company also promoted the drug to treat mentally ill boys -- even though it could cause them to grow breasts. Johnson &amp; Johnson is currently fighting a large number of individual lawsuits related to those accusations.&nbsp;</span></span></p>\n<p><span>In the settlement, Johnson &amp; Johnson pled guilty to “introducing a misbranded drug into interstate commerce.” But in a letter to its employees, company lawyers said they strongly dispute the government’s version of events and settled just to move on and avoid lengthy legal tie ups. &nbsp;</span></p>\n<p><span>By the way, the whistleblowers whose leaks spurred this investigation stand to gain about $168 million from the government’s taking.</span></p></div>","tags":["APM","Business","Johnson & Johnson","fraud"],"description":"In one of the biggest cases of health care fraud ever, J&J is being fined for improperly marketing a drug for treating schizophrenia.","audio":[{"meta":{"crop":"primary","width":"610","height":"340"},"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/99313930.jpg?itok=C8sa7EFc","type":"image/jpeg"},{"type":"audio/mpeg","format":"MP3","href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2013/11/05/marketplace_segment07_20131105_64.mp3","meta":{"duration":69,"api":{"href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2013/11/05/marketplace_segment07_20131105","type":"application/json"},"duration_hms":"00:01:09"}}]}